Bicalutamide (ICI-176334)

Catalog No.S1190

For research use only.

Bicalutamide (ICI-176334) is an androgen receptor (AR) antagonist with IC50 of 0.16 μM in LNCaP/AR(cs)cell line. Bicalutamide promotes autophagy.

Bicalutamide (ICI-176334) Chemical Structure

CAS No. 90357-06-5

Selleck's Bicalutamide (ICI-176334) has been cited by 40 publications

Purity & Quality Control

Choose Selective Androgen Receptor Inhibitors

Other Androgen Receptor Products

Biological Activity

Description Bicalutamide (ICI-176334) is an androgen receptor (AR) antagonist with IC50 of 0.16 μM in LNCaP/AR(cs)cell line. Bicalutamide promotes autophagy.
Targets
Androgen Receptor [1]
(LNCaP/AR(cs) cells)
0.16 μM
In vitro

Bicalutamide undergoes an antagonist-to-agonist switch, stimulating AR activity. Bicalutamide treatment of LNCaP/AR(cs) cells in absence of the synthetic androgen R1881 results in altered gene expression consistent with its well-documented agonist activity in context of AR overexpression. Bicalutamide induces cell proliferation in a dose-dependent manner, and only partially antagonized the effects of R1881. Bicalutamide treatment also results in a significant amount of nuclear AR, although less than that observed with R1881. Bicalutamide exhibits partial agonist activity as evidenced by induction of DNA binding at AR target genes and incomplete antagonism of the effects of R1881. In absence of R1881, Bicalutamide partially activates VP16-AR–mediated transcription, indicative of AR binding to DNA. In LNCaP/AR-luc cells with a stably integrates AR-driven luciferase reporter construct. In the presence of R1881, Bicalutamide shows only weak partial antagonism of VP16-AR–mediated transcription with an IC50 of 0.35 μM. [1] Micromolar bicalutamide causes a significant dose-dependent reduction in clonogenicity. [2] Dual inhibition of the AR and mTOR signaling pathways provides further benefit with the ridaforolimus-bicalutamide combination producing syner -gistic antiproliferative effects in prostate cancer cells in vitro when compared with each agent alone. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
human MDA-MB-453 cells NWjCWXhOTnWwY4Tpc44h[XO|YYm= Mm\2SIl{eGyjY3Xt[Y51KG:oIGuzTH1TOTh6MTDmdo9uKEGUIHnuJIh2dWGwIF3ERU1OSi12NUOgZ4VtdHNuIFXDOVA:OzFibl2= Mn\2NlM4OTN3Nke=
LNCaP cells M3;wcmZ2dmO2aX;uJIF{e2G7 Ml;lTY5pcWKrdHnvckBw\iCdM1jdMWRJXCCkaX7kbY5oKHSxIGS4O|dCKGGwZILv[4VvKHKnY3XweI9zKG:oIFzOR4FRKGOnbHzzMEBMcT1|NTDuUS=> NIfHOIUyPTZyM{m2NC=>
Freestyle293F cells NWC2XlJyTnWwY4Tpc44h[XO|YYm= MoXqTY5pcWKrdHnvckBw\iC5aXzkJJR6eGViQX7kdo9o\W5icnXj[ZB1d3JiKIXub45wf25ib4Lp[4lvMSCneIDy[ZN{\WRiaX6gSpJm\XO2eXzlNlk{TiClZXzsd{whUUN3ME2wMlA2PCEQvF2= M1SyOVI{OTl7NEe3
HEK293 cells MlzqSpVv[3Srb36gZZN{[Xl? NWrMc5FqOyCq M{S4UmRqe3CuYXPlcYVvfCCxZjDbNVcu[WyyaHGtcYV1cHmuLUPIYY1q[m:uZYLvcoUh\nKxbTDhcoRzd2enbjDy[YNmeHSxcjDlfJBz\XO|ZXSgbY4hUEWNMkmzJINmdGy|IHHmeIVzKDNiaILzMEBKSzVyPUW0JI5O NE\EZ2czOjN7MUCzNy=>
MDA453 cells M{j6TGZ2dmO2aX;uJIF{e2G7 MoDHSIl{eGyjY3Xt[Y51KG:oIGuzTH1FUFRiZoLvcUBpfW2jbjDhcoRzd2enbjDy[YNmeHSxcjDpckBOTEF2NUOgZ4VtdHNuIFvpQVY1KG6P M3vqSFE5OjlzNkS0
human MDA-MB-453 cells NFnXOGdHfW6ldHnvckBie3OjeR?= NIryTnhFcXOybHHj[Y1mdnRib3[gX|NJZUSKVDDmdo9uKEGUIHnuJIh2dWGwIF3ERU1OSi12NUOgZ4VtdHNuIFnDOVA:PjRibl2= MV[yNFU5PDZzMB?=
COS1 cells NEPHXVhHfW6ldHnvckBie3OjeR?= NHjZ[3VCdnSjZ3;ubZN1KGGldHn2bZR6KGGpYXnud5QheFOJNT30ZYdo\WRiaIXtZY4h[W6mcn;n[Y4hemWlZYD0c5Ih\XiycnXzd4VlKGmwIFPPV|Eh[2WubIOgZZN{\XO|ZXSgZZMhemWmdXP0bY9vKGmwIILlZ4VxfG:{LX3l[IlifGWmIITyZY5{[3KrcITpc45idCCjY4Tpeol1gSCkeTDBVk1z\We3bHH0[YQhemG2IIDyc4Jie2mwIIDyc41wfGW{IH\yZYdu\W62IHTybZZmdiCoaYLl[ox6KGy3Y3nm[ZJie2VicnXwc5J1\XJiYYPzZZktKEmFNUC9NE4xQDZ7IN88US=> M1ficlI2PjR4NkS5
HeLa cells NF\oSIdHfW6ldHnvckBie3OjeR?= MWHBcpRi\2:waYP0JIFkfGm4aYT5JIF1KGi3bXHuJIFv\HKxZ3XuJJJm[2WydH;yJIV5eHKnc4Pl[EBqdiCKZVzhJINmdGy|IHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZiZHnofYRzd3Snc4Tvd5Rmem:wZTDpcoR2[2WmIITyZY5{[3KrcITpc45idCCjY4Tpeol1gSCkeTDy[ZBwenSncjDn[Y5mKGG|c3H5MEBKSzVyPUCuNVQh|ryP MUexO|gxPDJ{OR?=
CV1 cells M4nNbmZ2dmO2aX;uJIF{e2G7 NES1TWxDcW6maX7nJIFn\mmwaYT5JJRwKGi3bXHuJIFv\HKxZ3XuJJJm[2WydH;yJIV5eHKnc4Pl[EBqdiCFVkGgZ4VtdHNuIFvpQVAvOTVzIN88US=> NU\RO|ZtOTd{NUe4N|g>
monkey COS7 cells MV3GeY5kfGmxbjDhd5NigQ>? M4jCb2JqdmSrbnegZYZncW6rdImgeI8hcHWvYX6gZY5lem:pZX6gdoVk\XC2b4Kg[ZhxemW|c3XkJIlvKG2xbnvlfUBEV1N5IHPlcIx{KGK7IIfoc4xmKGOnbHygZolv\GmwZzDhd5NigSxiS3m9NE4yPTFizszN MnXnNVg1PDJ7MUK=
COS7 cells NFHYTXRHfW6ldHnvckBie3OjeR?= NX\FfGZTSWexbnnzeEBi[3Srdnn0fUBifCCqdX3hckBidmS{b3flckBz\WOncITvdkBYPzRzQzDteZRidnRiZYjwdoV{e2WmIHnuJGNQWzdiY3XscJMh[XO|ZYPz[YQh[XNibIXjbYZmemG|ZTDhZ5Rqfmm2eTDh[pRmeiB{NDDodpMh[nlicnXwc5J1\XJiZ3Xu[UBie3OjeTygSWM2OD1yLkG4JO69VQ>? NIP2O4EzOjB7NEK3PS=>
CHO-K1 cells NYLVUYtJTnWwY4Tpc44h[XO|YYm= Mn3VNkBp M4q4OGRqe3CuYXPlcYVvfCCxZjDbN2hedWmkb3zldo9v\SCocn;tJIh2dWGwIFHSJIV5eHKnc4Pl[EBqdiCFSF:tT|Eh[2WubIOgZYZ1\XJiMjDodpMh[nlic3PpcpRqdGyjdHnvckBkd3WwdHnu[{whUUN3ME2wMlIh|ryP M{\HNlIxOzhzM{[x
human HT-3 cell M3zjXmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MknSTY5pcWKrdHnvckBw\iCqdX3hckBJXC1|IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD63N|E{PCEQvF2= MoniV2FPT0WU
human LNCAP cells Mnu0VJJwdGmoZYLheIlwdiCjc4PhfS=> M3PPU|Mh\GG7cx?= NUH4UpAxSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDMUmNCWCClZXzsd{Bi\nSncjCzJIRigXNuIFnDOVA:OC55M{K3JO69VQ>? NHL6[XEzPjB2NkOxNy=>
human PC3 cells MkXYSpVv[3Srb36gZZN{[Xl? MknNSIl{eGyjY3Xt[Y51KG:oIGuzTH1TOTh6MTDmdo9uKGGwZILv[4VvKHKnY3XweI9zKGmwIHj1cYFvKFCFMzDj[YxteyxiRVO1NF01NjNizszN NEDyToEzPTV7MUC2Oi=>
human 22Rv1 cells M{[0TGZ2dmO2aX;uJIF{e2G7 NYX3d4lGOyCmYYnz Ml;JRY51[WexbnnzeEBi[3Srdnn0fUBifCCjbnTyc4dmdiC{ZXPldJRweiCKOEe0XUBufXSjboSgLJVvc26xd36gc5Jq\2mwKTDlfJBz\XO|ZXSgbY4hcHWvYX6gNlJTfjFiY3XscJMh[XO|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBFUFRvaX7keYNm\CClZXzsJIdzd3e2aDDh[pRmeiB|IHThfZMh[nliV2PUMVgh[XO|YYmsJGlEPTB;ND62JO69VQ>? Ml\lNlQ6ODB3OEi=
human CCF-STTG1 cell NHvjcoFIem:5dHigbY5pcWKrdHnvckBie3OjeR?= Ml;NTY5pcWKrdHnvckBw\iCqdX3hckBES0ZvU2TUS|Eh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5Nige,:jDDJR|UxRTRwOUK5Nlkh|ryP NWjaPGVbW0GQR1XS
human SCC-25 cell NG\RXGJIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MnnnTY5pcWKrdHnvckBw\iCqdX3hckBUS0NvMkWgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME22MlA5PjV4IN88US=> MnnYV2FPT0WU
human MKN45 cell MoTlS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MlnTTY5pcWKrdHnvckBw\iCqdX3hckBOU052NTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPU[uPVYxPSEQvF2= NIn0VJZUSU6JRWK=
human ES5 cell NGnYR3hIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NUCwSIlNUW6qaXLpeIlwdiCxZjDoeY1idiCHU{WgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME24MlYyOTV2IN88US=> NIHwc3hUSU6JRWK=
human SK-MEL-3 cell NXTySGRmT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NUjiU2JGUW6qaXLpeIlwdiCxZjDoeY1idiCVSz3NSWwuOyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTFyLkC5OlQh|ryP NWPySYhZW0GQR1XS
human PC-3 cell M{DqVmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 Ml;rTY5pcWKrdHnvckBw\iCqdX3hckBRSy1|IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MUCuNlc6OSEQvF2= NUjEN|JlW0GQR1XS
human NOS-1 cell MU\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NIjmXIhKdmirYnn0bY9vKG:oIHj1cYFvKE6RUz2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NVEvOjlzNzFOwG0> M3;wdnNCVkeHUh?=
human LB1047-RCC cell NFTse29Iem:5dHigbY5pcWKrdHnvckBie3OjeR?= M1XSOGlvcGmkaYTpc44hd2ZiaIXtZY4hVEJzMES3MXJESyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTF{LkK1N{DPxE1? MXPTRW5ITVJ?
human CAMA-1 cell MV\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? Mki5TY5pcWKrdHnvckBw\iCqdX3hckBESU2DLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xNk4{QTJ4IN88US=> MlLEV2FPT0WU
human SAS cell NUnpWIlpT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NV7PPJdsUW6qaXLpeIlwdiCxZjDoeY1idiCVQWOgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xN{4{ODhzIN88US=> NVfHcG9MW0GQR1XS
human NCI-H2228 cell MnX2S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MVXJcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KMkKyPEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVE{Njd3M{Gg{txO MXrTRW5ITVJ?
human NCI-H187 cell NIrjV|hIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MYfJcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KMUi3JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NVYvPjZzNjFOwG0> MVjTRW5ITVJ?
human BFTC-905 cell NYXBZ4lPT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NVjJdXlZUW6qaXLpeIlwdiCxZjDoeY1idiCERmTDMVkxPSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTF5LkS4OVch|ryP MkTpV2FPT0WU
human G-361 cell NGP0[mdIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MUjJcohq[mm2aX;uJI9nKGi3bXHuJGcuOzZzIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MUeuPFI3KM7:TR?= MnrYV2FPT0WU
human DU145 cells NIDWco1EgXSxdH;4bYPDqGG|c3H5 M3PuS|czKGh? MYTDfZRwfG:6aXPpeJkh[WejaX7zeEBGWmGucHjhMYRm\mmlaXXueEBpfW2jbjDEWVE1PSClZXzsd{BmgHC{ZYPzbY5oKEWUYnX0ZUBie3Onc4Pl[EBieyCpcn;3eIghcW6qaXLpeIlwdiCjZoTldkA4OiCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwQVE5KM7:TR?= NWCyUG95W0GQR1XS
human SW780 cell NEDEbJdIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M1W3VmlvcGmkaYTpc44hd2ZiaIXtZY4hW1d5OECgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfS=> MnvlV2FPT0WU
human BB49-HNC cell NFfmWYJIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M3\zU2lvcGmkaYTpc44hd2ZiaIXtZY4hSkJ2OT3IUmMh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0yQC57NUOyJO69VQ>? MXvTRW5ITVJ?
human KALS-1 cell MWPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MUfJcohq[mm2aX;uJI9nKGi3bXHuJGtCVFNvMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUG5MlY3OzVizszN M3f4cnNCVkeHUh?=
human AU565 cell MU\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NYfTfW1vUW6qaXLpeIlwdiCxZjDoeY1idiCDVUW2OUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVE6Njd2MEKg{txO MVrTRW5ITVJ?
human NCI-H2087 cell NF7WOWdIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MmnqTY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSEKwPFch[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0zOS5yNUmxJO69VQ>? M1;ScnNCVkeHUh?=
human RVH-421 cell NGTCZZZIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MmfzTY5pcWKrdHnvckBw\iCqdX3hckBTXkhvNEKxJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NlEvPTd7NTFOwG0> NUPrV5kyW0GQR1XS
human SK-CO-1 cell MlnmS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NWXZWJJTUW6qaXLpeIlwdiCxZjDoeY1idiCVSz3DU{0yKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OjFwOEi3NkDPxE1? MkDaV2FPT0WU
human KU-19-19 cell NILKPZdIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MY\Jcohq[mm2aX;uJI9nKGi3bXHuJGtWNTF7LUG5JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NlIvODJ2MjFOwG0> NFHKOpFUSU6JRWK=
human NB6 cell NV[yfGhuT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MnfqTY5pcWKrdHnvckBw\iCqdX3hckBPSjZiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1{Mj65NVM2KM7:TR?= NHvJUmpUSU6JRWK=
human RO82-W-1 cell Mne1S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NF;CSVBKdmirYnn0bY9vKG:oIHj1cYFvKFKROEKtW{0yKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OjNwMUOxPEDPxE1? Mn60V2FPT0WU
human LNCAP cells MkXCR5l1d3SxeHnjxsBie3OjeR?= NGfZbZAzKGSjeYO= MX7DfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDMUmNCWCClZXzsd{Bie3Onc4Pl[EBieyClZXzsJJZq[WKrbHn0fUBi\nSncjCyJIRigXNiYomgZ4VtdCClb4XueIlv\yCvZYToc4QtKEmFNUC9NlMvPzlizszN Mmr4NlM4OjdyNES=
human CTB-1 cell M2PrfGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MWrJcohq[mm2aX;uJI9nKGi3bXHuJGNVSi1zIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MkSuOVU{PiEQvF2= MVHTRW5ITVJ?
human SW48 cell M2\iRWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NGTCWY1KdmirYnn0bY9vKG:oIHj1cYFvKFOZNEigZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yOE43PTR4IN88US=> NIr0S2hUSU6JRWK=
human TCCSUP cell NXrCbFloT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MXnJcohq[mm2aX;uJI9nKGi3bXHuJHRES1OXUDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUK0MlczOzJizszN M1vV[3NCVkeHUh?=
human DK-MG cell NVflfJd5T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NVzIUYpNUW6qaXLpeIlwdiCxZjDoeY1idiCGSz3NS{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVI1Njh7MUeg{txO MmDOV2FPT0WU
human ST486 cell M1jYNWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NX3WWZRpUW6qaXLpeIlwdiCxZjDoeY1idiCVVES4OkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVI2Njd2NkSg{txO NGPvN2dUSU6JRWK=
human H4 cell NI[weo5Iem:5dHigbY5pcWKrdHnvckBie3OjeR?= MlHqTY5pcWKrdHnvckBw\iCqdX3hckBJPCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTJ4Lkm0OVgh|ryP MlrhV2FPT0WU
human SBC-1 cell MXHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NX;vUHk5UW6qaXLpeIlwdiCxZjDoeY1idiCVQlOtNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVI5NjN3MEeg{txO MVjTRW5ITVJ?
human CAS-1 cell NWT0TW5DT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M{\OSGlvcGmkaYTpc44hd2ZiaIXtZY4hS0GVLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yPE43Ojl2IN88US=> MkXOV2FPT0WU
human OAW-42 cell MofDS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NGLzcmlKdmirYnn0bY9vKG:oIHj1cYFvKE:DVz20NkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVI5NjdzOUWg{txO MUjTRW5ITVJ?
human HCC1954 cell MWTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MVXJcohq[mm2aX;uJI9nKGi3bXHuJGhESzF7NUSgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yPE44PTJ3IN88US=> NHfE[lZUSU6JRWK=
human MDA-MB-453 cell Mn;QS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MnK0TY5pcWKrdHnvckBw\iCqdX3hckBOTEFvTVKtOFU{KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OjlwOUC3JO69VQ>? NInOPXhUSU6JRWK=
human MCF7 cell NYXMTplGT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= Mni5TY5pcWKrdHnvckBw\iCqdX3hckBOS0Z5IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;M{muN|AyKM7:TR?= NU[3VJR[W0GQR1XS
human PC3 cells M4DJNWZ2dmO2aX;uJIF{e2G7 M3fabVExOOPCgN88US=> NGKyU5k1QCCq NXvieHlEUW6qaXLpeIlwdiCxZjDhZ5RqdiCkYYPl[EBxe2W3ZH;wc4Rq[SCob4LtZZRqd25iaX6gZY5lem:pZX6t[IVx\W6mZX70JIh2dWGwIGDDN{Bk\WyuczDheEAyODBidV2gZYZ1\XJiNEigbJJ{KGK7IFTBVGkhe3SjaX7pcoch[mG|ZXSg[ox2d3Knc3PlcoNmKG2rY4Lvd4NweHliYYPzZZk> MYmyNlY4Ojl6NB?=
human PC3 cells MVfGeY5kfGmxbjDhd5NigQ>? MoewNE4yNTFizszN NYO0VnNKSWexbnnzeEBi[3Srdnn0fUBifCCjbnTyc4dmdiC{ZXPldJRweiCZN{SxR{BufXSjboSg[ZhxemW|c3XkJIlvKGi3bXHuJHBEOyClZXzsd{Bie3Onc4Pl[EBieyC|dHnteYxifGmxbjDv[kBz\WOncITvdkB1emGwc3HjeIl3[XSrb36gZZQhOC5zIITvJFEhfU1iYomgcJVkcW[ncnHz[UBz\XCxcoTldkBo\W6nIHHzd4F6 M3fJV|IzOTd3Nkm0
Assay
Methods Test Index PMID
Western blot Cytosolic AR / Nuclear AR 30833616
Growth inhibition assay Cell viability 27994514
In vivo Single bicalutamide reduces tumor growth by 79%, at defined submaximal doses. The ridaforolimus-bicalutamide combination exhibits improved and potent antitumor activity, almost completely abrogating tumor growth. The combination is also well tolerated, as evidenced by no significant changes in body weight over the course of treatment. Plasma PSA levels are again tightly linked to tumor growth in the combination-treated mice. [3]

Protocol (from reference)

Kinase Assay:[1]
  • Whole-cell competitive binding assays:

    Whole-cell competitive binding assays are performed in LNCaP/AR(codon-switch) (LNCaP/AR(cs)) (harbors a mixture of exogenous wild-type AR and endogenous mutant AR (T877A)) and cells propagated in Iscove's or RPMI media supplemented with 10% fetal bovine serum, or during the assay with 10% charcoal-stripped, dextran-treated fetal bovine serum (CSS). Cells are pre-incubated with 18F-FDHT, increasing concentrations (1pM to 1μM) of cold Bicalutamide are added, and the assay is performed to measure specific uptake of 18F-FDHT (4). IC50 values are determined using a one site binding model with least squares curve fitting and R2 > 0.99.

Cell Research:[3]
  • Cell lines: C4-2 cell
  • Concentrations: 0-1 μM
  • Incubation Time: 72 hours
  • Method: Exponentially growing C4-2 cells are plated into two 96-well plates and incubated overnight at 37 ˚C. Twenty-four hours later one plate is aspirated and stored at -80 ˚C and the other treated with 10-fold serial concentrations of ridaforolimus (1000 nM to 0.0001 nM) or vehicle (ethanol). Following 72 hours culture at 37 ˚C, the plates are assessed simultaneously for cell growth using the Cy qUANT Cell Proliferation Assay kit. Bicalutamide and Ridaforolimus combination proliferation assays are performed similarly except cell growth is determined as the change in cell number between vehicle control and compound treated cells after 72 hours in culture.
Animal Research:[3]
  • Animal Models: Male nude mice bearing C4-2 cells
  • Dosages: 10 mg/kg
  • Administration: Administered via p.o.

Solubility (25°C)

In vitro

Chemical Information

Molecular Weight 430.37
Formula

C18H14F4N2O4S

CAS No. 90357-06-5
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles CC(CS(=O)(=O)C1=CC=C(C=C1)F)(C(=O)NC2=CC(=C(C=C2)C#N)C(F)(F)F)O

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04573231 Recruiting Drug: 18F-DCFPyL Breast Cancer|HER2-negative Breast Cancer|Metastatic Breast Cancer University of Wisconsin Madison May 24 2021 Phase 2
NCT04443062 Recruiting Drug: 177Lu-PSMA-617 Prostate Cancer Radboud University|Prostaatkankerstichting|Advanced Accelerator Applications July 20 2020 Phase 2
NCT02910050 Unknown status Drug: Bicalutamide|Drug: Aromatase Inhibitor Breast Cancer Xu fei|Sun Yat-sen University January 2016 Phase 2
NCT02614859 Active not recruiting Drug: Bicalutamide|Drug: Metformin and Bicalutamide Cancer of Prostate Fox Chase Cancer Center|National Cancer Institute (NCI) December 1 2015 Phase 2

(data from https://clinicaltrials.gov, updated on 2022-01-17)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Bicalutamide (ICI-176334) | Bicalutamide (ICI-176334) ic50 | Bicalutamide (ICI-176334) price | Bicalutamide (ICI-176334) cost | Bicalutamide (ICI-176334) solubility dmso | Bicalutamide (ICI-176334) purchase | Bicalutamide (ICI-176334) manufacturer | Bicalutamide (ICI-176334) research buy | Bicalutamide (ICI-176334) order | Bicalutamide (ICI-176334) mouse | Bicalutamide (ICI-176334) chemical structure | Bicalutamide (ICI-176334) mw | Bicalutamide (ICI-176334) molecular weight | Bicalutamide (ICI-176334) datasheet | Bicalutamide (ICI-176334) supplier | Bicalutamide (ICI-176334) in vitro | Bicalutamide (ICI-176334) cell line | Bicalutamide (ICI-176334) concentration | Bicalutamide (ICI-176334) nmr